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cBackground:
Venous thromboembolism (VTE) is a common and serious condition in
which a blood clot develops within the venous circulation. The Centers
for Disease Control and Prevention quotes an incidence of approximately
1-2 per 1000 people in the USA yearly. Risk factors are numerous and
can be divided into acquired (e.g. age, trauma, surgery, medical
conditions, medication), inherited (e.g. antithrombin deficiency, protein S
deficiency) and mixed (e.g. hyperhomocysteinemia).
Use of estrogen-containing medications is a known risk factor for VTE.
There have been no documented case reports of VTE in female
astronauts during spaceflight in the published literature. The oral
contraceptive pill (OCP) is the most commonly reported method of
menstrual cycle suppression, but OCP usage doubles the risk of VTE.
Current VTE risk prediction models do not include the spaceflight
environment or the physiological changes associated with it.
Objectives:
Identify and estimate the specific risk of VTE for female astronauts as a 
result of taking hormonal contraception for menstrual cycle control.
Hypothesis:
We predict spaceflight does not increase the risk of VTE compared to 
the terrestrial population because of the excellent health of the 
crewmembers, which in turn, reduces their risk from all the other 
known risk factors.
Method:
A systematic review of the literature was conducted to identify and
quantify the terrestrial risk factors for VTE. Studies involving analogue
populations, e.g. military personnel, were also reviewed due to
similarities in usage of the OCP for menstrual suppression. The Lifetime
Surveillance of Astronaut Health (LSAH) department at NASA provided
data on each terrestrial risk factor before and after a spaceflight mission
per female astronaut. This permitted an estimate of the change in each
risk predictor in relation to spaceflight to be calculated.
Results:
The most commonly identifiable terrestrial risks for VTE are not
applicable to the female astronaut population. This is likely due to
selection processes as well as training practices astronauts need to
maintain.
Potential risks relevant to female astronauts include:
•Hormonal contraception – OCP usage increases the VTE risk to 9-10
per 10,000 per year compared to 4-5 per 10,000 per year when not using
hormonal contraception
•Multiple long distance flights during training – When flights are ≥ 4
hours, risk of VTE is 21.5 per 100,000 flights, however, concurrent OCP
use increases this risk to 55.3 per 100,000 flights. Any two hour increase
in air travel duration increases the VTE risk by 26%.
•Immobility during Soyuz training – physical inactivity for >41 hours
per week increases the risk of pulmonary embolism by 2.34 (95% CI 1.3
– 4.2)
•Minor injuries as a result of pre-flight or in-flight activities – a minor
injury in the past prior three months leads to an adjusted odd ratio of
3.5 for developing a VTE (95% CI 2.8 – 4.3)
•Hematological factors – anaemia (microcytic and macrocytic),
thrombocytosis, hyperhomocysteinaemia and nutrient deficiencies all
increase the risk of VTE.
The majority of female astronauts on long duration missions chose to
use the oral contraceptive pill pre-flight and in-flight.
Results:
This pilot analysis used grouped data from 27 female crewmembers who 
used oral contraceptives on either long or short duration missions. 
Values are presented as means. Hematological factors for which LSAH 
data was requested included:
• Hemoglobin (Hb) – With an Hb <1st centile, the odds ratio of
VTE risk is 3.4. This was not the case for our female astronaut
population. Hematinics also did not reflect nutrient
deficiencies amongst our astronaut population.
• A Mean Corpuscular Volume (MCV) <1st centile or >99th
centile has an adjusted odds ratio of VTE risk of 1.95 and 2.65
respectively. This was not depicted in our data set.
• Hematocrit (Hct) – a 5% rise in Hct increases the risk of
VTE by 1.25. The Hct did not rise in our astronaut population
after spaceflight.
• Increased reticulocyte counts indicate new red blood cell
formation and potential increase in blood viscosity and thus
risk of VTE. This rose but only by 4.6%. High platelet counts
indicate a hypercoaguable blood status and therefore an
increased risk of VTE. The overall rise was 3.6%.
Conclusions
This study is still in progress and data is awaited on muscle injury rates
in-flight as well as homocysteine levels in relation to spaceflight.
Estimations are yet to be made on immobility times during specific
training activities. Additional statistical analyses and comparisons of
short vs. long-duration mission data are planned.
With the data that are available, we conclude the risk for VTE in female
astronauts is not higher than the general population also using hormonal
contraception. The crewmembers are a fit and healthy group of
individuals. Astronaut selection processes are likely to “select-out” the
most common terrestrial risk factors for VTE. There are, however,
training activities which could increase periodic risk of VTE amongst the
female astronauts. Care should be taken during these times.
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